SDN-1014

SDN-1014 is a preclinical **glycoconjugate immunostimulator** being developed by **Sidanis Pharma** as an **antiviral immunostimulator** and **host defense modifier** for viral infections, including hepatitis and influenza such as bird flu. Rather than directly targeting a viral protein, the program is described as selectively activating the immune system to enhance host recognition and clearance of viral pathogens, consistent with an innate and broader antiviral immunomodulatory mechanism. No discrete molecular target, formulation, route, or dosage form has been publicly disclosed.

Other names

glycoconjugate immunostimulatorantiviral immunostimulatorhost defense modifier